Clinical Trials
2 trialsNCT04925141 2021-06-14
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4 Completed
NCT01660906 2016-11-22
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Bristol-Myers Squibb
Phase 4 Completed